Mana.bio Announces Strategic Leadership Additions and Upcoming Presentation at ASGCT 2026 Annual Meeting

Mana.bio announced the appointment of Thaminda Ramanayake as a member of its board of directors, Michelle Lynn-Hall as a board observer, and Guy Van Meter as strategic advisor. These additions bring deep expertise in mRNA therapeutics, LNP delivery, business development, and strategic partnerships to support the company's next phase of growth.

Mana.bio will also present new data at the ASGCT 2026 Annual Meeting (May 11–15, 2026, Boston, MA), the premier scientific conference in cell and gene therapy. The Abstract ID: 1083, titled "Machine Learning-Driven Design of Lipid Nanoparticles for In Vivo T-Cell Engineering," will highlight the company's proprietary ML platform and its application towards the development of passive-targeted LNPs for in vivo T-cell transfection. The poster session will take place on Tuesday May 12th, 2026 at 5:30 PM.

Read the full press release here